Comments
Suven Life Sciences Limited has reported a net profit of Rs 3.36 crore for the quarter ended June 30, 2011, up marginally from Rs 3.44 crore in the corresponding quarter of last fiscal.
The company revenues stood at Rs 44.84 crore (Rs 36.31 crore) a 23.48 per cent growth for the quarter under review. A highlight of the quarter was the continued spending on Research & Development (R&D) of Rs 7.48 crore or 16.68 per cent of the revenue for the quarter.
The results are visible in the Hyderabad-based company obtaining 13 product patents. Suven's drug discovery pipeline is also strong with molecules at various stages of trials targeting dementia, Huntington's disease, Parkinson's, Schizophrenia etc.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.